Is Celgene Now a Value Stock?
May 29, 2018
Biotech drug company Celgene (CELG) has lost around half its value since last Fall. At this point, is the stock a good value?
Research Reports
All the News on Celgene is Bad — But the P/E is Just 11
March 6, 2018
All the recent news on Celgene (CELG) has been bad lately, But profits are expected to climb 14% this year and the stock has a P/E of just 11. So is the stock a good buy or goodbye?
Celgene Sinks After Cutting Long-Term Targets
January 10, 2018
Celgens (CELG) sank 20% after the company reported last qtr’s profits, and lowered long-term profit targets. There’s multiple issues going on here, but the stock is now cheap with a P/E of 12.
Biotech Breakout Are Good News For Celgene
August 30, 2017
Biotech stocks were breaking out today — big time. Will that be enough to push shares of Celgene (CELG) out of its two year base? Let’s take a look.
Celgene Breaks Out As Biotechs Break Out As Well
June 22, 2017
Shares of Celgene (CELG) broke out to a new 52-week high yesterday on high volume as the Biotech sector roared higher — and broke out as well.
Biotechs — and Celgene — Poised to Break Out to New Highs
March 2, 2017
Celgene (CELG) and the Biotech sector are both on the verge of breaking out to new highs. But does CELG have what it takes to power higher?
Celgene’s Profits Continue to Expand, But its Stock is Stuck in Neutral
December 22, 2016
Celgene (CELG) is having another banner year with profits expected to climb 26% this year. But like many growth stocks, CELG is stuck in neutral.
Clinton or Trump? Celgene is Expected to Grow Profits 20% Regardless
September 18, 2016
With multiple drugs expected to go through Phase III in the next two years, Celgene (CELG) is expected to grow profits 20% a year regardless of who is elected President.
Celgene Isn’t Getting the Respect that it Deserves
June 6, 2016
Shares of Celgene (CELG) aren’t doing much, but the Biotech has a lot going for it, and isn’t getting the respect it deserves.
With Shares of Celgene Down, Long-term Upside is Amazing
March 1, 2016
Celgene (CELG) is down around 20% from a year ago as the Biotechs have been weak. But with risk comes opportunity, and now CELG has 35% upside to my Fair Value.
Looking Good for the Long Term
January 2, 2016
Celgene (CELG) popped after it settled a patent case regarding Revlimid, and the stock is looking good for the long term.
Celgene Buys Receptos
August 6, 2015
Celgene (CELG) buys Receptos, and investors send CELG stock to a new All Time High. Here’s why.
2016 Could Be Huge
June 8, 2015
Analysts forecast Celgene (CELG) will have strong profit growth in 2016. But is it 30% or 40%?
$12.50 by 2020
February 18, 2015
Celgene’s (CELG) management has a target of $12.50 in EPS by 2020. Here’s what that means for CELG.
Should be a Banner 2015
November 20, 2014
I think 2015 will be a year where money flows away from big internet names and into Celgene (CELG).
Celgene Broke Out
August 20, 2014
Shares of Celgene (CELG) Just broke out, are on their way to $100, and I think CELG’s worth $132 in 2015.
A Sleeping Giant
May 28, 2014
Shares of Celgene (CELG) might be resting at the moment, but this stock is a sleeping giant ready to wake.
Biotechs Are On A Roll
February 27, 2014
Biotech stocks like Celgene (CELG) are the rage these days, and CELG is one of the steadiest of the bunch.
Still a Bright Future Ahead
November 19, 2013
I bought Celgene (CELG) last year for $69. Now after it’s more than doubled there is still a bright future ahead — especially in 2015.
Ten in Fifteen
August 27, 2013
Celgene (CELG) had a sizable increase in earnings estimates, and is well on track to make a whopping $10 in 2015.
Take Profits, Sell Half
May 21, 2013
Celgene (CELG) has been one of the best large cap stocks to own this year. But now CELG’s almost doubled. I think its time to take profits and sell half.
A Solid Move Higher
February 26, 2013
Celgene (CELG) is in the midst of a solid move higher pushed by good profit growth and a still undervalued stock.
Underappreciated
January 30, 2013
Celgene (CELG) is one of the most under appreciated stocks in the stock market. This stock has it all — profit growth, low PE, and momentum.
Trending Higher
December 5, 2012
Shares of Celgene (CELG) have been trending higher as of late. Backed by an all-green one-year chart, the trend is your friend.
Turned Back Up
July 31, 2012
Celgene (CELG) has turned back up so I will add it to the Aggressive Growth Portfolio and Growth Portfolio and will sell Body Central (BODY).
Too Low to Go
May 30, 2012
Body Central (BODY) warned after reporting earnings last quarter. BODY dropped from $29 to $15 on the news. Now its too low to sell.
Not In Style
March 22, 2012
Body Central (BODY) didn’t stock the right clothes for Spring, thus profits will be light the next 2 quarters. I’ll sell BODY from the Aggressive Growth Portfolio.
Gaining Attention
January 26, 2012
Body Central (BODY) is getting noticed by institutional investors, who need to realize this is one of the best retailers to own in 2012.
Under the Radar
October 14, 2011
Body Central (BODY) continues to fly under the radar of investors minds. Now with a P/E of only 16, there’s good upside. But BODY needs to get moving.
Growth Mode
July 22, 2011
Body Central (BODY) is in growth mode, and this specialty retailer is a bargain at 20 times earnings. One thing I wasn’t impressed with is quarterly estimates didn’t increase after BODY reported.
My New BFF
April 18, 2011
My new BFF has a boomin BODY.
Today I will sell Cognizant Tech. Solutions (CTSH) and Bridgepoint Education (BPI) and buy Body Central (BODY) in the Growth Portfolio. I like BODY so much that it will also replace Express Scripts (ESRX) in the Aggressive Growth Portfolio.